Overview of Dr. Niesvizky
Dr. Ruben Niesvizky is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Universidad Nacional Autonoma de Mexico and has been in practice 32 years. Dr. Niesvizky accepts several types of health insurance, listed below. He is one of 64 doctors at New York-Presbyterian Hospital and one of 25 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Hematology. He also speaks multiple languages, including Hebrew and Spanish. He has more than 100 publications and over 500 citings.
Office
425 E 61st St
Fl 8
New York, NY 10065Fax+1 212-746-8961
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1990 - 1994
- Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1988 - 1990
- Universidad Nacional Autonoma de MexicoClass of 1985
Certifications & Licensure
- OR State Medical License 1993 - Present
- NY State Medical License 1994 - 2025
Awards, Honors, & Recognition
- Top doctors Newsweek, 2015
- New York Magazine: Top Doctors Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Join now to see all
Clinical Trials
- Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma Start of enrollment: 2005 Jun 01
- Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma Start of enrollment: 2004 Dec 01
- Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Start of enrollment: 2007 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 173 citationsA Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6Linda B. Baughn, Maurizio Di Liberto, Kaida Wu, Peter L. Toogood, Tracey Louie
Cancer Research. 2006-08-01 - 203 citationsSafety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple my...Shaji Kumar, Jesus G. Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P. Laubach
The Lancet. Oncology. 2014-12-01 - 156 citationsPhase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myelomaShaji Kumar, William I. Bensinger, Todd M. Zimmerman, Craig B. Reeder, James R. Berenson
Blood. 2014-08-14
Journal Articles
- Carfilzomib vs Bortezomib in Patients with Multiple Myeloma and Renal Failure: A Subgroup Analysis of ENDEAVORRuben Niesvizky, David Siegel, Ralph Boccia, Blood
Abstracts/Posters
- Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)Ruben Niesvizky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain AmyloidosisRuben Niesvizky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not ...Ruben Niesvizky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
- Blood Test May Guide Multiple Myeloma Immunotherapy UseJuly 27th, 2024
- Routine Blood Test May Guide Use of Multiple Myeloma ImmunotherapyJuly 24th, 2024
- A Day in the Life of a Nurse Who Works 10-Hour Shifts in an NYC Cancer Unit Keeping Patients Comfortable in the Midst of a National Drug ShortageAugust 21st, 2019
- Join now to see all
Professional Memberships
- Member
- Member
Other Languages
- Hebrew, Spanish
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPOGHI PPO
Great West PPO
HIP of New York - Select PPO
MagnaCare PPO
MVP Healthcare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: